Amyloid precursor protein & endosomal-lysosomal dysfunction in Alzheimer's disease: Inseparable partners in a multifactorial disease

FASEB Journal

Volumn 31, Issue 7, 2017, Pages 2729-2743

  Nixon, Ralph A ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoliprotein E; Autophagy; Cholinergic neurodegeneration; Down syndrome; Presenilin

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; CHOLESTEROL; PRESENILIN 1; PRESENILIN 2; RAB PROTEIN; RAB5 PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; DEGENERATIVE DISEASE; ENDOSOME; GENE MUTATION; HUMAN; LYSOSOME; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PATHOLOGY; PRIORITY JOURNAL; PROTEIN PROCESSING; SYNAPSE; TAUOPATHY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ENDOSOMES; GENE EXPRESSION REGULATION; HUMANS; LYSOSOMES;

EID: 85021679704     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.201700359     Document Type: Article

References (217)

1. Bissig, C., and Gruenberg, J. (2013) Lipid sorting and multivesicular endosome biogenesis. Cold Spring Harb. Perspect. Biol. 5, a016816.
2. Settembre, C., and Ballabio, A. (2014) Lysosomal adaptation: how the lysosome responds to external cues. Cold Spring Harb. Perspect. Biol. 6, a016907.
3. Cosker, K. E., and Segal, R. A. (2014) Neuronal signaling through endocytosis. Cold Spring Harb. Perspect. Biol. 6, a020669.
4. Di Fiore, P. P., and von Zastrow, M. (2014) Endocytosis, signaling, and beyond. Cold Spring Harb. Perspect. Biol. 6, a016865.
5. Bright, N. A., Davis, L. J., and Luzio, J. P. (2016) Endolysosomes are the principal intracellular sites of acid hydrolase activity. Curr. Biol. 26, 2233-2245.
6. Xu, H., andRen, D. (2015) Lysosomal physiology. Annu. Rev. Physiol. 77, 57-80.
7. Perez-Gonzalez, R., Gauthier, S. A., Kumar, A., and Levy, E. (2012) The exosome secretory pathway transports amyloid precursor protein carboxyl-Terminal fragments from the cell into the brain extracellular space. J. Biol. Chem. 287, 43108- 43115.
8. Eitan, E., Suire, C., Zhang, S., and Mattson, M. P. (2016) Impact of lysosome status on extracellular vesicle content and release. Ageing Res. Rev. 32, 65-74.
9. Cheng, X., Zhang, X., Yu, L., and Xu, H. (2015) Calcium signaling in membrane repair. Semin. Cell Dev. Biol. 45, 24-31.
10. Lee, S., Sato, Y., and Nixon, R. A. (2011) Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy. J. Neurosci. 31, 7817-7830.
11. Small, S.A., and Petsko, G.A. (2015) Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. Nat. Rev. Neurosci. 16, 126-132.
12. Muhammad, A., Flores, I., Zhang, H., Yu, R., Staniszewski, A., Planel, E., Herman, M., Ho, L., Kreber, R., Honig, L. S., Ganetzky, B., Duff, K., Arancio, O., and Small, S. A. (2008) Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc. Natl. Acad. Sci. USA 105, 7327-7332.
13. Woodruff, G., Reyna, S.M., Dunlap, M., Van Der Kant, R., Callender, J.A., Young, J.E., Roberts, E.A., and Goldstein, L. S. (2016) Defective transcytosis ofAPPandlipoproteins inhumaniPSC-derivedneurons with familial Alzheimer's disease mutations. Cell Rep. 17, 759-773.
14. Cataldo, A. M., Peterhoff, C. M., Troncoso, J. C., Gomez-Isla, T., Hyman, B. T., and Nixon, R. A. (2000) Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 157, 277-286.
15. Urwin, H., Ghazi-Noori, S., Collinge, J., and Isaacs, A. (2009) The role of CHMP2B in frontotemporal dementia. Biochem. Soc. Trans. 37, 208-212.
16. Cabeza, C., Figueroa, A., Lazo, O. M., Galleguillos, C., Pissani, C., Klein, A., Gonzalez-Billault, C., Inestrosa, N. C., Alvarez, A. R., Zanlungo, S., and Bronfman, F. C. (2012) Cholinergic abnormalities, endosomal alterations and up-regulation of nerve growth factor signaling in Niemann-Pick type C disease. Mol. Neurodegener. 7, 11.
17. Cataldo, A. M., Barnett, J. L., Pieroni, C., and Nixon, R. A. (1997) Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-Amyloidogenesis. J. Neurosci. 17, 6142-6151.
18. Jiang, Y., Mullaney, K. A., Peterhoff, C. M., Che, S., Schmidt, S. D., Boyer-Boiteau, A., Ginsberg, S. D., Cataldo, A. M., Mathews, P. M., and Nixon, R. A. (2010) Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl. Acad. Sci. USA 107, 1630-1635.
19. Israel, M. A., Yuan, S.H., Bardy, C., Reyna, S.M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., Carson, C. T., Laurent, L. C., Marsala, M., Gage, F.H., Remes, A. M., Koo, E. H., and Goldstein, L. S. (2012) Probing sporadic and familial Alzheimer'sdiseaseusing induced pluripotent stemcells. Nature 482, 216-220.
20. Kim, S., Sato, Y., Mohan, P. S., Peterhoff, C., Pensalfini, A., Rigoglioso, A., Jiang, Y., and Nixon, R. A. (2016) Evidence that the rab5 effector APPL1mediates APP-betaCTF-induced dysfunction of endosomes in Down syndrome and Alzheimer's disease. Mol. Psychiatry 21, 707-716.
21. Xu, W., Weissmiller, A. M., White, J. A. II, Fang, F., Wang, X., Wu, Y., Pearn, M. L., Zhao, X., Sawa, M., Chen, S., Gunawardena, S., Ding, J., Mobley, W. C., and Wu, C. (2016) Amyloid precursor proteinmediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. J. Clin. Invest. 126, 1815-1833.
22. Cataldo, A. M., Mathews, P. M., Boiteau, A. B., Hassinger, L. C., Peterhoff, C.M., Jiang, Y., Mullaney, K., Neve, R. L., Gruenberg, J., and Nixon, R. A. (2008) Down syndrome fibroblast model of Alzheimer-related endosome pathology: Accelerated endocytosis promotes late endocytic defects. Am. J. Pathol. 173, 370-384.
23. McPhie, D. L., Coopersmith, R., Hines-Peralta, A., Chen, Y., Ivins, K. J., Manly, S. P., Kozlowski, M. R., Neve, K. A., and Neve, R. L. (2003) DNA synthesis and neuronal apoptosis caused by familial Alzheimer diseasemutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3. J. Neurosci. 23, 6914-6927.
24. Laifenfeld, D., Patzek, L. J., McPhie, D. L., Chen, Y., Levites, Y., Cataldo, A. M., and Neve, R. L. (2007) Rab5 mediates an amyloid precursor protein signaling pathway that leads to apoptosis. J. Neurosci. 27, 7141-7153.
25. Chen, Y., Huang, X., Zhang, Y. W., Rockenstein, E., Bu, G., Golde, T. E., Masliah, E., and Xu, H. (2012) Alzheimer's b-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of b-Amyloid. J. Neurosci. 32, 11390-11395.
26. Choi, J. H., Kaur, G., Mazzella, M. J., Morales-Corraliza, J., Levy, E., and Mathews, P. M. (2013) Early endosomal abnormalities and cholinergic neuron degeneration in amyloid-b protein precursor transgenic mice. J. Alzheimers Dis. 34, 691-700.
27. Yan, X.-X.C., Zhang, X.-M., Macklin, N., Cai, H., Luo, X.-G., Struble, R. G., Rose, G. M., and Patrylo, P. R. (2011) BACE1 elevation is involved in amyloid plaque pathogenesis in the triple transgenic model of Alzheimer's disease: profiling an early-onset axonal accumulation of putative APP b-carboxyl terminal fragments. Neuroscience 2011: 41st Annual Neuroscience Meeting, presentation 354.317, Society for Neuroscience, Washington, DC.
28. Nistor, M., Don, M., Parekh, M., Sarsoza, F., Goodus, M., Lopez, G. E., Kawas, C., Leverenz, J., Doran, E., Lott, I.T., Hill, M., and Head, E. (2007) Alpha-And beta-secretase activity as a function of age and beta-Amyloid in Down syndrome and normal brain. Neurobiol. Aging 28, 1493-1506.
29. Holsinger, R. M., McLean, C. A., Beyreuther, K., Masters, C. L., and Evin, G. (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann. Neurol. 51, 783-786.
30. Fukumoto, H., Cheung, B. S., Hyman, B. T., and Irizarry, M. C. (2002) Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch. Neurol. 59, 1381-1389.
31. Tesco, G., Koh, Y. H., Kang, E. L., Cameron, A. N., Das, S., Sena-Esteves, M., Hiltunen, M., Yang, S. H., Zhong, Z., Shen, Y., Simpkins, J. W., and Tanzi, R. E. (2007) Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron 54, 721-737.
32. Liang, B., Duan, B. Y., Zhou, X.P., Gong, J.X., andLuo, Z. G. (2010) Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J. Biol. Chem. 285, 27737-27744.
33. Yeates, E. F., and Tesco, G. (2016) The endosome-Associated deubiquitinating enzymeUSP8 regulatesBACE1 enzyme ubiquitination and degradation. J. Biol. Chem. 291, 15753-15766.
34. Thomas, R. S., Henson, A., Gerrish, A., Jones, L., Williams, J., and Kidd, E. J. (2016) Decreasing the expression of PICALM reduces endocytosis and the activity of b-secretase: implications for Alzheimer's disease. BMC Neurosci. 17, 50.
35. Song, W. J., Son, M. Y., Lee, H.W., Seo, H., Kim, J.H., and Chung, S.H. (2015) Enhancement of BACE1 activity by p25/Cdk5-mediated phosphorylation in Alzheimer's disease. PLoS One 10, e0136950.
36. Natunen, T., Takalo, M., Kemppainen, S., Leskela, S., Marttinen, M., Kurkinen, K. M., Pursiheimo, J. P., Sarajarvi, T., Viswanathan, J., Gabbouj, S., Solje, E., Tahvanainen, E., Pirttimaki, T., Kurki, M., Paananen, J., Rauramaa, T., Miettinen, P., Makinen, P., Leinonen, V., Soininen, H., Airenne, K., Tanzi, R. E., Tanila, H., Haapasalo, A., and Hiltunen, M. (2016) Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenicmouse brain and cell-based models. Neurobiol. Dis. 85, 187-205.
37. Devi, L., and Ohno, M. (2014) PERK mediates eIF2a phosphorylation responsible for BACE1 elevation, CREB dysfunction and neurodegeneration in a mouse model of Alzheimer's disease. Neurobiol. Aging 35, 2272-2281.
38. He, X., Li, F., Chang, W. P., and Tang, J. (2005) GGA proteins mediate the recycling pathway ofmemapsin 2 (BACE). J. Biol. Chem. 280, 11696-11703.
39. Schnoder, L., Hao, W., Qin, Y., Liu, S., Tomic, I., Liu, X., Fassbender, K., and Liu, Y. (2016) Deficiency of neuronal p38aMAPKattenuates amyloid pathology in Alzheimer disease mouse and cell models through facilitating lysosomal degradation of BACE1. J. Biol. Chem. 291, 2067-2079.
40. Okada, H., Zhang, W., Peterhoff, C., Hwang, J. C., Nixon, R. A., Ryu, S. H., and Kim, T. W. (2010) Proteomic identification of sorting nexin 6 as a negative regulator of BACE1-mediated APP processing. FASEB J. 24, 2783-2794.
41. Araki, W. (2016) Post-Translational regulation of the b-secretase BACE1. Brain Res. Bull. 126, 170-177.
42. Wang, H., Li, R., and Shen, Y. (2013) b-Secretase: its biology as a therapeutic target in diseases. Trends Pharmacol. Sci. 34, 215-225.
43. Rhinn, H., Fujita, R., Qiang, L., Cheng, R., Lee, J.H., and Abeliovich, A. (2013) Integrative genomics identifies APOE e4 effectors in Alzheimer's disease. Nature 500, 45-50.
44. Calafate, S., Flavin, W., Verstreken, P., and Moechars, D. (2016) Loss of bin1 promotes the propagation of tau pathology. Cell Rep. 17, 931-940.
45. Das, U., Wang, L., Ganguly, A., Saikia, J.M., Wagner, S.L., Koo, E.H., and Roy, S. (2016) Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway.Nat.Neurosci. 19, 55-64.
46. Miaczynska, M., Christoforidis, S., Giner, A., Shevchenko, A., Uttenweiler-Joseph, S., Habermann, B., Wilm, M., Parton, R. G., and Zerial, M. (2004) APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. Cell 116, 445-456.
47. Zhu, G., Chen, J., Liu, J., Brunzelle, J. S., Huang, B., Wakeham, N., Terzyan, S., Li, X., Rao, Z., Li, G., and Zhang, X.C. (2007) Structure of theAPPL1BAR-PHdomainandcharacterizationof its interaction with Rab5. EMBO J. 26, 3484-3493.
48. Beel, A. J., Mobley, C. K., Kim, H. J., Tian, F., Hadziselimovic, A., Jap, B., Prestegard, J. H., and Sanders, C. R. (2008) Structural studies of the transmembrane C-Terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor? Biochemistry 47, 9428-9446.
49. Beel, A. J., Sakakura, M., Barrett, P. J., and Sanders, C. R. (2010) Direct binding of cholesterol to the amyloid precursor protein: An important interaction in lipid-Alzheimer's disease relationships? Biochim. Biophys. Acta 1801, 975-982.
50. Ehehalt, R., Keller, P., Haass, C., Thiele, C., and Simons, K. (2003) Amyloidogenic processing of the Alzheimer betaamyloid precursor protein depends on lipid rafts. J. Cell Biol. 160, 113-123.
51. Lee, J. R., Hahn, H. S., Kim, Y. H., Nguyen, H. H., Yang, J.M., Kang, J. S., and Hahn, M. J. (2011)Adaptor proteincontaining PHdomain, PTB domain and leucine zipper (APPL1) regulates the protein level ofEGFRbymodulating its trafficking. Biochem. Biophys. Res. Commun. 415, 206-211.
52. Danson, C., Brown, E., Hemmings, O. J., McGough, I. J., Yarwood, S., Heesom, K. J., Carlton, J.G., Martin-Serrano, J., May, M.T., Verkade, P., and Cullen, P. J. (2013) SNX15 links clathrin endocytosis to the PtdIns3P early endosome independently of the APPL1 endosome. J. Cell Sci. 126, 4885-4899.
53. Flores-Rodriguez, N., Kenwright, D. A., Chung, P. H., Harrison, A. W., Stefani, F., Waigh, T. A., Allan, V. J., and Woodman, P. G. (2015) ESCRT-0 marks an APPL1-independent transit route for EGFR between the cell surface and the EEA1-positive early endosome. J. Cell Sci. 128, 755-767.
54. Kalaidzidis, I., Miaczynska, M., Brewínska-Olchowik, M., Hupalowska, A., Ferguson, C., Parton, R. G., Kalaidzidis, Y., and Zerial, M. (2015) APPL endosomes are not obligatory endocytic intermediates but act as stable cargo-sorting compartments. J. Cell Biol. 211, 123-144.
55. Hupalowska, A., Pyrzynska, B., and Miaczynska, M. (2012) APPL1 regulates basal NF-kB activity by stabilizing NIK. J. Cell Sci. 125, 4090-4102.
56. Ryu, J., Galan, A. K., Xin, X., Dong, F., Abdul-Ghani, M. A., Zhou, L., Wang, C., Li, C., Holmes, B. M., Sloane, L. B., Austad, S. N., Guo, S., Musi, N., DeFronzo, R. A., Deng, C., White, M. F., Liu, F., and Dong, L. Q. (2014) APPL1 potentiates insulin sensitivity by facilitating the binding of IRS1/2 to the insulin receptor. Cell Rep. 7, 1227-1238.
57. Wang, J., Lu, W., Chen, L., Zhang, P., Qian, T., Cao, W., and Luo, J. (2016) Serine 707 of APPL1 is critical for the synaptic NMDA receptor-mediated akt phosphorylation signaling pathway. Neurosci. Bull. 32, 323-330.
58. Bohdanowicz, M., Balkin, D. M., De Camilli, P., and Grinstein, S. (2012) Recruitment of OCRL and Inpp5B to phagosomes by Rab5 and APPL1 depletes phosphoinositides and attenuates Akt signaling. Mol. Biol. Cell 23, 176-187.
59. Fu, X., Yang, Y., Xu, C., Niu, Y., Chen, T., Zhou, Q., and Liu, J. J. (2011) Retrolinkin cooperates with endophilin A1 to mediate BDNF-TrkB early endocytic trafficking and signaling from early endosomes. Mol. Biol. Cell 22, 3684-3698.
60. Lin, D. C., Quevedo, C., Brewer, N. E., Bell, A., Testa, J. R., Grimes, M. L., Miller, F. D., and Kaplan, D. R. (2006) APPL1 associates with TrkA and GIPC1 and is required for nerve growth factor-mediated signal transduction. Mol. Cell. Biol. 26, 8928-8941.
61. Ogawa, A., Yamazaki, Y., Nakamori, M., Takahashi, T., Kurashige, T., Hiji, M., Nagano, Y., Yamawaki, T., and Matsumoto, M. (2013) Characterization and distribution of adaptor protein containing a PH domain, PTB domain and leucine zipper motif (APPL1) in Alzheimer's disease hippocampus: An immunohistochemical study. Brain Res. 1494, 118-124.
62. Majumdar, D., Nebhan, C. A., Hu, L., Anderson, B., and Webb, D. J. (2011) An APPL1/Akt signaling complex regulates dendritic spine and synapse formation in hippocampal neurons. Mol. Cell. Neurosci. 46, 633-644.
63. Ferńandez-Monreal, M., Śanchez-Castillo, C., and Esteban, J. A. (2016) APPL1 gates long-Term potentiation through its plekstrin homology domain. J. Cell Sci. 129, 2793-2803.
64. Kessels, H. W., and Malinow, R. (2009) Synaptic AMPA receptor plasticity and behavior. Neuron 61, 340-350.
65. Brown, T. C., Tran, I. C., Backos, D. S., and Esteban, J. A. (2005) NMDA receptor-dependent activation of the small GTPase Rab5 drives the removal of synaptic AMPA receptors during hippocampal LTD. Neuron 45, 81-94.
66. Dhaka, A., Costa, R. M., Hu, H., Irvin, D. K., Patel, A., Kornblum, H. I., Silva, A. J., O'Dell, T. J., and Colicelli, J. (2003) TheRAS effector RIN1modulates the formation of aversivememories. J. Neurosci. 23, 748-757.
67. Park, M., Penick, E. C., Edwards, J. G., Kauer, J. A., and Ehlers, M. D. (2004) Recycling endosomes supply AMPA receptors for LTP. Science 305, 1972-1975.
68. Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S., and Malinow, R. (2006) AMPAR removal underlies Abetainduced synaptic depression and dendritic spine loss. Neuron 52, 831-843.
69. Koffie, R. M., Hyman, B. T., and Spires-Jones, T. L. (2011) Alzheimer's disease: synapses gone cold. Mol. Neurodegener. 6, 63.
70. Lauŕen, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., and Strittmatter, S. M. (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128-1132.
71. Renner, M., Lacor, P. N., Velasco, P. T., Xu, J., Contractor, A., Klein, W. L., and Triller, A. (2010) Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 66, 739-754.
72. Cirrito, J. R., Kang, J. E., Lee, J., Stewart, F. R., Verges, D. K., Silverio, L. M., Bu, G., Mennerick, S., and Holtzman, D. M. (2008) Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 58, 42-51.
73. Xu, W., Fitzgerald, S., Nixon, R. A., Levy, E., and Wilson, D. A. (2015) Early hyperactivity in lateral entorhinal cortex is associated with elevated levels of AbPP metabolites in the Tg2576 mouse model of Alzheimer's disease. Exp. Neurol. 264, 82-91.
74. Hamm, V. B., Bott, J. B., Heraud, C., Herbeaux, K., Strittmatter, C., Cassel, J. C., and Goutagny, R. (2014) b-CTF induced early behavioral and electrophysiological alterations in transgenic TgCRND8 mouse model of Alzheimer's disease. Neuroscience 2014: 44th Annual Neuroscience Meeting, presentation 307.318, Society for Neuroscience, Washington, DC.
75. Lauritzen, I., Pardossi-Piquard, R., Bauer, C., Brigham, E., Abraham, J. D., Ranaldi, S., Fraser, P., St-George-Hyslop, P., Le Thuc, O., Espin, V., Chami, L., Dunys, J., and Checler, F. (2012) The b-secretase-derived C-Terminal fragment of bAPP, C99, but not Ab, is a key contributor to early intraneuronal lesions in triple-Transgenic mouse hippocampus. J. Neurosci. 32, 16243-16255.
76. Lauritzen, I., Pardossi-Piquard, R., Bourgeois, A., Pagnotta, S., Biferi, M. G., Barkats, M., Lacor, P., Klein, W., Bauer, C., and Checler, F. (2016) Intraneuronal aggregation of the b-CTF fragment of APP (C99) induces Ab-independent lysosomal-Autophagic pathology. Acta. Neuropathol. 132, 257-276.
77. Mondragon-Rodriguez, S. M., Manseau, F., Gu, N., Boyce, R., and Williams, S. (2014) Early brain network alterations are correlated with b-CTF in Alzheimer's transgenic mouse model. Neuroscience 2014: 44th Annual Neuroscience Meeting, presentation 40.09, Society for Neuroscience, Washington, DC.
78. Tamayev, R., Matsuda, S., Giliberto, L., Arancio, O., and D'Adamio, L. (2011) APP heterozygosity averts memory deficit in knockin mice expressing theDanishdementiaBRI2mutant. EMBO J. 30, 2501-2509.
79. Tamayev, R., and D'Adamio, L. (2012) Inhibition of g-secretase worsensmemory deficits in a genetically congruousmousemodel of Danish dementia. Mol. Neurodegener. 7, 19.
80. Tamayev, R., Matsuda, S., Arancio, O., and D'Adamio, L. (2012) b- but not g-secretase proteolysis of APP causes synaptic and memory deficits in amouse model of dementia. EMBO Mol. Med. 4, 171-179.
81. Siḿon, A. M., Schiapparelli, L., Salazar-Colocho, P., Cuadrado-Tejedor, M., Escribano, L., Ĺopez de Maturana, R., Del Ŕio, J., Ṕerez-Mediavilla, A., and Frechilla, D. (2009) Overexpression of wild-Type human APP in mice causes cognitive deficits andpathological featuresunrelatedto Abeta levels. Neurobiol. Dis. 33, 369-378.
82. Choi, S.H., Park, C. H., Koo, J.W., Seo, J. H., Kim, H. S., Jeong, S. J., Lee, J.H., Kim, S. S., and Suh, Y.H. (2001) Memory impairment and cholinergic dysfunction by centrally administered Abeta and carboxyl-Terminal fragment of Alzheimer's APP in mice. FASEB J. 15, 1816-1818.
83. Kim, H. S., Kim, E. M., Kim, N. J., Chang, K. A., Choi, Y., Ahn, K. W., Lee, J.H., Kim, S., Park, C. H., and Suh, Y. H. (2004) Inhibition of histone deacetylation enhances the neurotoxicity induced by the C-Terminal fragments of amyloid precursor protein. J. Neurosci. Res. 75, 117-124.
84. Imbimbo, B. P., and Giardina, G. A. (2011) g-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr. Top. Med. Chem. 11, 1555-1570.
85. Holtzman, D. M., Li, Y., Parada, L. F., Kinsman, S., Chen, C. K., Valletta, J. S., Zhou, J., Long, J. B., and Mobley, W. C. (1992) p140trk mRNA marks NGF-responsive forebrain neurons: Evidence that trk gene expression is induced by NGF. Neuron 9, 465-478.
86. Sofroniew, M. V., Galletly, N. P., Isacson, O., and Svendsen, C. N. (1990) Survival of adult basal forebrain cholinergic neurons after loss of target neurons. Science 247, 338-342.
87. Grothe, M., Heinsen, H., and Teipel, S. J. (2012) Atrophy of the cholinergic basal forebrain over the adult age range and in early stages of Alzheimer's disease. Biol. Psychiatry 71, 805-813.
88. Schmitz, T. W., and Nathan Spreng, R.; Alzheimer's Disease Neuroimaging Initiative. (2016) Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology. Nat. Commun. 7, 13249.
89. Muth, K., Schonmeyer, R., Matura, S., Haenschel, C., Schroder, J., and Pantel, J. (2010) Mild cognitive impairment in the elderly is associatedwith volume loss of the cholinergic basal forebrainregion. Biol. Psychiatry 67, 588-591.
90. Mufson, E. J., Ma, S. Y., Dills, J., Cochran, E. J., Leurgans, S., Wuu, J., Bennett, D. A., Jaffar, S., Gilmor, M. L., Levey, A. I., and Kordower, J. H. (2002) Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J. Comp. Neurol. 443, 136-153.
91. Mufson, E. J., Bothwell, M., and Kordower, J.H. (1989) Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: A quantitative analysis across subregions of the basal forebrain. Exp. Neurol. 105, 221-232.
92. Salehi, A., Delcroix, J. D., Belichenko, P. V., Zhan, K., Wu, C., Valletta, J. S., Takimoto-Kimura, R., Kleschevnikov, A. M., Sambamurti, K., Chung, P. P., Xia, W., Villar, A., Campbell, W. A., Kulnane, L. S., Nixon, R.A., Lamb, B. T., Epstein, C. J., Stokin, G. B., Goldstein, L. S., andMobley, W.C. (2006) Increased App expression in a mousemodel of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51, 29-42.
93. Granholm, A. C., Sanders, L. A., and Crnic, L. S. (2000) Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp. Neurol. 161, 647-663.
94. Nishitomi, K., Sakaguchi, G., Horikoshi, Y., Gray, A. J., Maeda, M., Hirata-Fukae, C., Becker, A. G., Hosono, M., Sakaguchi, I., Minami, S. S., Nakajima, Y., Li, H. F., Takeyama, C., Kihara, T., Ota, A., Wong, P. C., Aisen, P. S., Kato, A., Kinoshita, N., and Matsuoka, Y. (2006) BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-Type mice. J. Neurochem. 99, 1555-1563.
95. McConlogue, L., Buttini, M., Anderson, J. P., Brigham, E. F., Chen, K. S., Freedman, S. B., Games, D., Johnson-Wood, K., Lee, M., Zeller, M., Liu, W., Motter, R., and Sinha, S. (2007) Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic Mice. J. Biol. Chem. 282, 26326- 26334.
96. Gout, I., Middleton, G., Adu, J., Ninkina, N. N., Drobot, L. B., Filonenko, V., Matsuka, G., Davies, A. M., Waterfield, M., and Buchman, V. L. (2000) Negative regulation of PI 3-kinase by Ruk, a novel adaptor protein. EMBO J. 19, 4015-4025.
97. Chen, B., Borinstein, S. C., Gillis, J., Sykes, V. W., and Bogler, O. (2000) The glioma-Associated protein SETA interacts with AIP1/Alix and ALG-2 and modulates apoptosis in astrocytes. J. Biol. Chem. 275, 19275-19281.
98. Missotten, M., Nichols, A., Rieger, K., and Sadoul, R. (1999) Alix, a novel mouse protein undergoing calcium-dependent interaction with the apoptosis-linked-gene 2 (ALG-2) protein. Cell Death Differ. 6, 124-129.
99. 2+-binding protein ALG-2 and Alzheimer's disease gene ALG-3. Science 271, 521-525.
100. 2+-dependent reaction. J. Biol. Chem. 274, 1533-1540.
101. Nikolaev, A., McLaughlin, T., O'Leary, D. D., and Tessier-Lavigne, M. (2009) APP bindsDR6 to trigger axonpruning and neurondeath via distinct caspases. Nature 457, 981-989.
102. Huang, Y. (2010) Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol. Med. 16, 287-294.
103. Nelson, P. T., Alafuzoff, I., Bigio, E.H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Del Tredici, K., Duyckaerts, C., Frosch, M. P., Haroutunian, V., Hof, P. R., Hulette, C.M., Hyman, B.T., Iwatsubo, T., Jellinger, K.A., Jicha, G.A., Kovari, E., Kukull, W. A., Leverenz, J. B., Love, S., Mackenzie, I. R., Mann, D. M., Masliah, E., McKee, A. C., Montine, T. J., Morris, J. C., Schneider, J. A., Sonnen, J. A., Thal, D. R., Trojanowski, J. Q., Troncoso, J. C., Wisniewski, T., Woltjer, R. L., and Beach, T. G. (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J. Neuropathol. Exp. Neurol. 71, 362-381.
104. Lane-Donovan, C., Philips, G. T., and Herz, J. (2014) More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration. Neuron 83, 771-787.
105. He, X., Cooley, K., Chung, C. H. Y., Dashti, N., and Tang, J. (2007) Apolipoprotein receptor 2 and X11 a/b mediate apolipoprotein E-induced endocytosisof amyloid-bprecursorprotein andb-secretase, leading to amyloid-b production. J. Neurosci. 27, 4052-4060.
106. Heeren, J., Grewal, T., Laatsch, A., Becker, N., Rinninger, F., Rye, K. A., and Beisiegel, U. (2004) Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation. J. Biol. Chem. 279, 55483-55492.
107. Rellin, L., Heeren, J., and Beisiegel, U. (2008) Recycling of apolipoprotein E is not associated with cholesterol efflux in neuronal cells. Biochim. Biophys. Acta 1781, 232-238.
108. Mauch, D. H., Nagler, K., Schumacher, S., Goritz, C., Muller, E. C., Otto, A., and Pfrieger, F. W. (2001) CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354-1357.
109. Barrett, P. J., Song, Y., VanHorn, W.D., Hustedt, E. J., Schafer, J.M., Hadziselimovic, A., Beel, A. J., and Sanders, C.R. (2012)The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 336, 1168-1171.
110. Ji, Z. S., Mullendorff, K., Cheng, I.H., Miranda, R. D., Huang, Y., and Mahley, R. W. (2006) Reactivity of apolipoprotein E4 and amyloid beta peptide: lysosomal stability and neurodegeneration. J. Biol. Chem. 281, 2683-2692.
111. Cossec, J. C., Marquer, C., Panchal, M., Lazar, A. N., Duyckaerts, C., and Potier, M.C. (2010) Cholesterol changes inAlzheimer's disease: methods of analysis and impact on the formation of enlarged endosomes. Biochim. Biophys. Acta 1801, 839-845.
112. Fu, R., Yanjanin, N. M., Elrick, M. J., Ware, C., Lieberman, A. P., and Porter, F. D. (2012) Apolipoprotein E genotype and neurological disease onset in Niemann-Pick disease, type C1. Am. J. Med. Genet. A. 158, 2775-2780.
113. Karch, C.M., and Goate, A.M. (2015) Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry 77, 43-51.
114. Larsen, K. E., and Sulzer, D. (2002) Autophagy in neurons: A review. Histol. Histopathol. 17, 897-908.
115. Ivy, G.O., Kanai, S., Ohta, M., Smith, G., Sato, Y., Kobayashi, M., and Kitani, K. (1989) Lipofuscin-like substances accumulate rapidly in brain, retina and internal organs with cysteine protease inhibition. Adv. Exp. Med. Biol. 266, 31-45, discussion 45-47.
116. Nixon, R. A. (2013) The role of autophagy in neurodegenerative disease. Nat. Med. 19, 983-997.
117. Felbor, U., Kessler, B., Mothes, W., Goebel, H. H., Ploegh, H. L., Bronson, R. T., and Olsen, B. R. (2002) Neuronal loss and brain atrophy inmice lacking cathepsins B and L. Proc. Natl. Acad. Sci. USA 99, 7883-7888.
118. Nixon, R. A., Wegiel, J., Kumar, A., Yu, W.H., Peterhoff, C., Cataldo, A., and Cuervo, A.M. (2005) Extensiveinvolvementof autophagy in Alzheimer disease: An immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 64, 113-122.
119. Lee, J. H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G., Uchiyama, Y., Westaway, D., Cuervo, A. M., and Nixon, R. A. (2010) Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141, 1146-1158.
120. Cataldo, A.M., Peterhoff, C.M., Schmidt, S. D., Terio, N. B., Duff, K., Beard, M., Mathews, P. M., and Nixon, R. A. (2004) Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J. Neuropathol. Exp. Neurol. 63, 821-830.
121. Cai, Y., Zhang, X. M., Macklin, L. N., Cai, H., Luo, X. G., Oddo, S., Laferla, F.M., Struble, R. G., Rose, G.M., Patrylo, P.R., andYan, X. X. (2012) BACE1 elevation is involved in amyloid plaque development in the triple transgenicmodel of Alzheimer's disease: differential Ab antibody labeling of early-onset axon terminal pathology. Neurotox. Res. 21, 160-174.
122. Boland, B., Kumar, A., Lee, S., Platt, F.M., Wegiel, J., Yu, W.H., and Nixon, R. A. (2008) Autophagy induction and autophagosome clearance in neurons: Relationship to autophagic pathology in Alzheimer's disease. J. Neurosci. 28, 6926-6937.
123. Yang, D. S., Kumar, A., Stavrides, P., Peterson, J., Peterhoff, C. M., Pawlik, M., Levy, E., Cataldo, A. M., and Nixon, R. A. (2008) Neuronal apoptosis and autophagy cross talk in aging PS/APP mice, a model of Alzheimer's disease. Am. J. Pathol. 173, 665-681.
124. Yamashita, N., and Kuruvilla, R. (2016) Neurotrophin signaling endosomes: biogenesis, regulation, and functions. Curr. Opin. Neurobiol. 39, 139-145.
125. Yu, W.H., Cuervo, A.M., Kumar, A., Peterhoff, C.M., Schmidt, S. D., Lee, J. H., Mohan, P. S., Mercken, M., Farmery, M. R., Tjernberg, L. O., Jiang, Y., Duff, K., Uchiyama, Y., Naslund, J., Mathews, P. M., Cataldo, A. M., and Nixon, R. A. (2005) Macroautophagy-A novel beta-Amyloid peptide-generating pathway activated in Alzheimer's disease. J. Cell Biol. 171, 87-98.
126. Mony, V. K., Benjamin, S., and O'Rourke, E. J. (2016) A lysosomecentered view of nutrient homeostasis. Autophagy 12, 619-631.
127. Yoon, S. Y., Choi, J. E., Yoon, J.H., Huh, J.W., and Kim, D.H. (2006) BACE inhibitor reduces APP-beta-C-Terminal fragment accumulationinaxonal swellingsof okadaic acid-inducedneurodegeneration. Neurobiol. Dis. 22, 435-444.
128. Villaseñor, R., Kalaidzidis, Y., and Zerial, M. (2016) Signal processing by the endosomal system. Curr. Opin. Cell Biol. 39, 53-60.
129. Cheng, F., Cappai, R., Lidfeldt, J., Belting, M., Fransson, L.A., and Mani, K. (2014) Amyloid precursor protein (APP)/APP-like protein 2 (APLP2) expression is required to initiateendosome-nucleus-Autophagosome trafficking of glypican-1-derived heparan sulfate. J. Biol. Chem. 289, 20871-20878.
130. Nguyen, K., and Rabenstein, D. L. (2016) Interaction of the heparin-binding consensus sequence of b-Amyloid peptides with heparin and heparin-derived oligosaccharides. J. Phys. Chem. B 120, 2187-2197.
131. Brendza, R. P., Bacskai, B. J., Cirrito, J. R., Simmons, K. A., Skoch, J. M., Klunk, W.E., Mathis, C. A., Bales, K. R., Paul, S. M., Hyman, B. T., and Holtzman, D.M. (2005) Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-Associated neuritic dystrophy in PDAPP transgenic mice. J. Clin. Invest. 115, 428-433.
132. Novotny, R., Langer, F., Mahler, J., Skodras, A., Vlachos, A., Wegenast-Braun, B. M., Kaeser, S. A., Neher, J. J., Eisele, Y. S., Pietrowski, M. J., Nilsson, K. P., Deller, T., Staufenbiel, M., Heimrich, B., and Jucker, M. (2016) Conversion of synthetic Ab to in vivo active seeds and amyloid plaque formation in a hippocampal slice culture model. J. Neurosci. 36, 5084-5093.
133. Yang, T., Li, S., Xu, H., Walsh, D.M., and Selkoe, D. J. (2017) Large soluble oligomers of amyloid b-protein fromAlzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate. J. Neurosci. 37, 152-163.
134. Frautschy, S. A., Horn, D. L., Sigel, J. J., Harris-White, M. E., Mendoza, J. J., Yang, F., Saido, T. C., and Cole, G. M. (1998) Protease inhibitor coinfusion with amyloid beta-protein results in enhanced deposition and toxicity in rat brain. J. Neurosci. 18, 8311-8321.
135. Frautschy, S. A., Yang, F., Calderon, L., and Cole, G. M. (1996) Rodent models of Alzheimer's disease: Rat A beta infusion approaches to amyloid deposits. Neurobiol. Aging 17, 311-321.
136. Cataldo, A. M., Barnett, J. L., Berman, S. A., Li, J., Quarless, S., Bursztajn, S., Lippa, C., and Nixon, R. A. (1995) Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: Evidence for early up-regulation of the endosomal-lysosomal system. Neuron 14, 671-680.
137. Cataldo, A. M., Hamilton, D. J., Barnett, J. L., Paskevich, P. A., and Nixon, R.A. (1996) Properties of the endosomal-lysosomal systemin the human central nervous system: disturbancesmarkmost neurons in populations at risk to degenerate in Alzheimer's disease. J. Neurosci. 16, 186-199.
138. Bordi, M., Berg, M. J., Mohan, P. S., Peterhoff, C. M., Alldred, M. J., Che, S., Ginsberg, S. D., and Nixon, R. A. (2016) Autophagy flux in CA1 neurons of Alzheimer hippocampus: increased induction overburdens failing lysosomes to propel neuritic dystrophy. Autophagy 12, 2467-2483.
139. Nixon, R. A., and Cataldo, A.M. (2006) Lysosomal systempathways: genes to neurodegeneration in Alzheimer's disease. J. Alzheimers Dis. 9 (3 Suppl), 277-289.
140. Yang, D. S., Stavrides, P., Mohan, P. S., Kaushik, S., Kumar, A., Ohno, M., Schmidt, S. D., Wesson, D., Bandyopadhyay, U., Jiang, Y., Pawlik, M., Peterhoff, C. M., Yang, A. J., Wilson, D. A., George-Hyslop, P., Westaway, D., Mathews, P. M., Levy, E., Cuervo, A. M., and Nixon, R. A. (2011) Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain 134, 258-277.
141. Yang, D. S., Stavrides, P., Saito, M., Kumar, A., Rodriguez-Navarro, J. A., Pawlik, M., Huo, C., Walkley, S. U., Saito, M., Cuervo, A. M., and Nixon, R. A. (2014) Defective macroautophagic turnover of brain lipids in the TgCRND8 Alzheimer mouse model: prevention by correcting lysosomal proteolytic deficits. Brain 137, 3300-3318.
142. + homeostasis via TRPML1 by regulating vATPase-mediated lysosome acidification. Cell Rep. 12, 1430-1444.
143. Xue, X., Wang, L. R., Sato, Y., Jiang, Y., Berg, M., Yang, D. S., Nixon, R. A., and Liang, X. J. (2014) Single-walled carbon nanotubes alleviate autophagic/lysosomal defects in primary glia from a mouse model of Alzheimer's disease. Nano Lett. 14, 5110-5117.
144. Yang, D. S., Stavrides, P., Kumar, A., Jiang, Y., Mohan, P. S., Ohno, M., Dobrenis, K., Davidson, C. D., Saito, M., Pawlik, M., Huo, C., Walkley, S. U., and Nixon, R. A. (2017) Cyclodextrin has conflicting actions on autophagy flux in vivo in brains of normal and Alzheimer model mice. Hum. Mol. Genet. 26, 843-859.
145. Nixon, R. A., Jiang, Y., Sato, Y., Im, E., Bordi, M., Colacurcio, D., Pensalfini, A., Rigoglioso, A., and Mohan, P. (2017) APP-b CTFmediated pathological endosome signaling also disrupts lysosomal function in Down syndrome (DS). AD/PD 2017: 13th International Congress on Alzheimer's and Parkinson's Diseases, presentation A01.f.009.
146. Giudetti, A.M., Romano, A., Lavecchia, A.M., and Gaetani, S. (2016) The role of brain cholesterol and its oxidized products in Alzheimer's disease. Curr. Alzheimer Res. 13, 198-205.
147. Gamba, P., Testa, G., Gargiulo, S., Staurenghi, E., Poli, G., and Leonarduzzi, G. (2015) Oxidized cholesterol as the driving force behind the development of Alzheimer's disease. Front. Aging Neurosci. 7, 119.
148. Kavcǐc, N., Pegan, K., and Turk, B. (2016) Lysosomes in programmed cell death pathways: from initiators to amplifiers. [E-pub ahead of print] Biol. Chem. doi:10.1515/hsz-2016-0252.
149. Yamashima, T. (2016) Can 'calpain-cathepsin hypothesis' explain Alzheimer neuronal death? Ageing Res. Rev. 32, 169-179.
150. Ǵomez-Sintes, R., Ledesma, M. D., and Boya, P. (2016) Lysosomal cell death mechanisms in aging. Ageing Res. Rev. 32, 150-168.
151. Boya, P., and Kroemer, G. (2008) Lysosomal membrane permeabilization in cell death. Oncogene 27, 6434-6451.
152. Aits, S., andJäattela, M. (2013) Lysosomal cell deathat a glance. J. Cell Sci. 126, 1905-1912.
153. Tian, Y., Chang, J. C., Greengard, P., and Flajolet, M. (2014) The convergence of endosomal and autophagosomal pathways: implications for APP-CTF degradation. Autophagy 10, 694-696.
154. Tian, Y., Chang, J. C., Fan, E. Y., Flajolet, M., and Greengard, P. (2013) Adaptor complex AP2/PICALM, through interaction with LC3, targets Alzheimer's APP-CTF for terminal degradation via autophagy. Proc. Natl. Acad. Sci. USA 110, 17071-17076.
155. Siman, R., Mistretta, S., Durkin, J. T., Savage, M. J., Loh, T., Trusko, S., and Scott, R.W. (1993) Processing of the beta-Amyloid precursor. Multiple proteases generate and degrade potentially amyloidogenic fragments. J. Biol. Chem. 268, 16602-16609.
156. Bustamante, H. A., Rivera-Dictter, A., Cavieres, V. A., Muñoz, V. C., Gonźalez, A., Lin, Y., Mardones, G. A., and Burgos, P. V. (2013) Turnover of C99 is controlled by a crosstalk between ERAD and ubiquitin-independent lysosomal degradation in human neuroglioma cells. PLoS One 8, e83096.
157. Ling, D., Magallanes, M., and Salvaterra, P.M. (2014) Accumulation of amyloid-like Ab1-42 in AEL (autophagy-endosomal-lysosomal) vesicles: potential implications for plaque biogenesis. ASN Neuro 6, e00139.
158. Kopan, R., and Ilagan, M. X. (2004) Gamma-secretase: proteasome of the membrane? Nat. Rev. Mol. Cell Biol. 5, 499-504.
159. Kumar-Singh, S., Theuns, J., Van Broeck, B., Pirici, D., Vennekens, K., Corsmit, E., Cruts, M., Dermaut, B., Wang, R., and Van Broeckhoven, C. (2006) Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum. Mutat. 27, 686-695.
160. Kuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., Segers-Nolten, I., Van Der Werf, K., Subramaniam, V., Braeken, D., Callewaert, G., Bartic, C., D'Hooge, R., Martins, I. C., Rousseau, F., Schymkowitz, J., and De Strooper, B. (2010) Neurotoxicity of Alzheimer's disease Ab peptides is induced by small changes in the Ab42 to Ab40 ratio. EMBO J. 29, 3408-3420.
161. Sun, L., Zhou, R., Yang, G., and Shi, Y. (2017) Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Ab42 andAb40 peptides by g-secretase. Proc.Natl. Acad. Sci. USA 114, E476-E485.
162. Pitsi, D., and Octave, J.N. (2004) Presenilin 1 stabilizes theC-Terminal fragment of the amyloid precursor protein independently of gammasecretase activity. J. Biol. Chem. 279, 25333-25338.
163. De Jonghe, C., Esselens, C., Kumar-Singh, S., Craessaerts, K., Serneels, S., Checler, F., Annaert, W., Van Broeckhoven, C., and De Strooper, B. (2001) Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-Terminal fragment stability. Hum.Mol. Genet. 10, 1665-1671.
164. Duggan, S. P., and McCarthy, J.V. (2016) Beyond g-secretase activity: Themultifunctional nature of presenilins in cell signalling pathways. Cell. Signal. 28, 1-11.
165. Jayne, T., Newman, M., Verdile, G., Sutherland, G., Munch, G., Musgrave, I., Moussavi Nik, S. H., and Lardelli, M. (2016) Evidencefor and against a pathogenic role of reduced g-secretase activity in familial Alzheimer's disease. J. Alzheimers Dis. 52, 781-799.
166. Schroder, B., and Saftig, P. (2016) Intramembraneproteolysiswithin lysosomes. Ageing Res. Rev. 32, 51-64.
167. Sannerud, R., Esselens, C., Ejsmont, P., Mattera, R., Rochin, L., Tharkeshwar, A. K., De Baets, G., DeWever, V., Habets, R., Baert, V., Vermeire, W., Michiels, C., Groot, A. J., Wouters, R., Dillen, K., Vints, K., Baatsen, P., Munck, S., Derua, R., Waelkens, E., Basi, G. S., Mercken, M., Vooijs, M., Bollen, M., Schymkowitz, J., Rousseau, F., Bonifacino, J. S., Van Niel, G., De Strooper, B., and Annaert, W. (2016) Restricted location of PSEN2/g-secretase determines substrate specificity and generates an intracellular Ab pool. Cell 166, 193-208.
168. Bagshaw, R. D., Pasternak, S.H., Mahuran, D. J., and Callahan, J. W. (2003) Nicastrin is a resident lysosomalmembrane protein. Biochem. Biophys. Res. Commun. 300, 615-618.
169. Pasternak, S. H., Bagshaw, R. D., Guiral, M., Zhang, S., Ackerley, C. A., Pak, B. J., Callahan, J.W., and Mahuran, D. J. (2003) Presenilin- 1, nicastrin, amyloidprecursor protein, andgamma-secretase activity are co-localized in the lysosomal membrane. J. Biol. Chem. 278, 26687-26694.
170. + (V)-ATPase interactome: identification of proteins involved in trafficking, folding, assembly and phosphorylation. Sci. Rep. 5, 14827.
171. Colacurcio, D. J., and Nixon, R. A. (2016) Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease. Ageing Res. Rev. 32, 75-88.
172. Williamson, W. R., and Hiesinger, P. R. (2010) On the role of v-ATPase V0a1-dependent degradation in Alzheimer disease. Commun. Integr. Biol. 3, 604-607.
173. Hughes, A. L., and Gottschling, D. E. (2012) An early age increase in vacuolar pH limits mitochondrial function and lifespan in yeast. Nature 492, 261-265.
174. Ruckenstuhl, C., Netzberger, C., Entfellner, I., Carmona-Gutierrez, D., Kickenweiz, T., Stekovic, S., Gleixner, C., Schmid, C., Klug, L., Sorgo, A. G., Eisenberg, T., Buttner, S., Mariño, G., Koziel, R., Jansen-Durr, P., Frohlich, K. U., Kroemer, G., and Madeo, F. (2014) Lifespan extension by methionine restriction requires autophagy-dependent vacuolar acidification. PLos Genet. 10, e1004347.
175. Molin, M., and Demir, A. B. (2014) Linking peroxiredoxin and vacuolar-ATPase functions in calorie restriction-mediated life span extension. Int. J. Cell Biol. 2014, 913071.
176. Belinson, H., Lev, D., Masliah, E., and Michaelson, D. M. (2008) Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits. J. Neurosci. 28, 4690-4701.
177. Ji, Z. S., Miranda, R. D., Newhouse, Y.M., Weisgraber, K.H., Huang, Y., andMahley, R.W. (2002) Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal leakage and apoptosis in neuronal cells. J. Biol. Chem. 277, 21821-21828.
178. Ohmi, K., Kudo, L. C., Ryazantsev, S., Zhao, H. Z., Karsten, S. L., and Neufeld, E. F. (2009) Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy. Proc. Natl. Acad. Sci. USA 106, 8332-8337.
179. Ryazantsev, S., Yu, W. H., Zhao, H. Z., Neufeld, E. F., and Ohmi, K. (2007) Lysosomal accumulation of SCMAS (subunit c of mitochondrial ATP synthase) in neurons of the mouse model of mucopolysaccharidosis III B. Mol. Genet. Metab. 90, 393-401.
180. McBrayer, M., and Nixon, R. A. (2013) Lysosome and calcium dysregulation inAlzheimer's disease: partners incrime. Biochem. Soc. Trans. 41, 1495-1502.
181. Rao, M. V., McBrayer, M. K., Campbell, J., Kumar, A., Hashim, A., Sershen, H., Stavrides, P. H., Ohno, M., Hutton, M., and Nixon, R. A. (2014) Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. J. Neurosci. 34, 9222-9234.
182. Zhang, Z., Song, M., Liu, X., Kang, S. S., Kwon, I. S., Duong, D. M., Seyfried, N. T., Hu, W. T., Liu, Z., Wang, J. Z., Cheng, L., Sun, Y. E., Yu, S. P., Levey, A. I., and Ye, K. (2014) Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nat. Med. 20, 1254-1262.
183. Basurto-Islas, G., Grundke-Iqbal, I., Tung, Y. C., Liu, F., and Iqbal, K. (2013) Activation of asparaginyl endopeptidase leads to tau hyperphosphorylation in Alzheimer disease. J. Biol. Chem. 288, 17495-17507.
184. Berger, Z., Ravikumar, B., Menzies, F. M., Oroz, L. G., Underwood, B. R., Pangalos, M. N., Schmitt, I., Wullner, U., Evert, B. O., O'Kane, C. J., and Rubinsztein, D. C. (2006) Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15, 433-442.
185. Wang, Y., Martinez-Vicente, M., Kruger, U., Kaushik, S., Wong, E., Mandelkow, E. M., Cuervo, A. M., and Mandelkow, E. (2009) Tau fragmentation, aggregation and clearance: The dual role of lysosomal processing. Hum. Mol. Genet. 18, 4153-4170.
186. Dolan, P. J., and Johnson, G. V. (2010) A caspase cleaved formof tau is preferentially degraded through the autophagy pathway. J. Biol. Chem. 285, 21978-21987.
187. Caccamo, A., Majumder, S., Richardson, A., Strong, R., and Oddo, S. (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and tau: Effects on cognitive impairments. J. Biol. Chem. 285, 13107-13120.
188. Khurana, V., Elson-Schwab, I., Fulga, T. A., Sharp, K. A., Loewen, C. A., Mulkearns, E., Tyynela, J., Scherzer, C. R., and Feany, M. B. (2010) Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo. PLos Genet. 6, e1001026.
189. Hamano, T., Gendron, T. F., Causevic, E., Yen, S. H., Lin, W. L., Isidoro, C., Deture, M., and Ko, L. W. (2008) Autophagiclysosomal perturbation enhances tau aggregation in transfectants with induced wild-Type tau expression. Eur. J. Neurosci. 27, 1119-1130.
190. Ginsberg, S. D., Alldred, M. J., Counts, S. E., Cataldo, A. M., Neve, R. L., Jiang, Y., Wuu, J., Chao, M. V., Mufson, E. J., Nixon, R. A., and Che, S. (2010) Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol. Psychiatry 68, 885-893.
191. Bahr, B. A., and Bendiske, J. (2002) The neuropathogenic contributions of lysosomal dysfunction. J. Neurochem. 83, 481-489.
192. Florez-McClure, M. L., Hohsfield, L.A., Fonte, G., Bealor, M. T., and Link, C. D. (2007) Decreased insulin-receptor signaling promotes the autophagic degradation of beta-Amyloid peptide in C. elegans. Autophagy 3, 569-580.
193. Heinrich, M., Wickel, M., Schneider-Brachert, W., Sandberg, C., Gahr, J., Schwandner, R., Weber, T., Saftig, P., Peters, C., Brunner, J., Kronke, M., and Schutze, S. (1999) Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J. 18, 5252-5263.
194. Nixon, R. A. (2007) Autophagy, amyloidogenesis and Alzheimer disease. J. Cell Sci. 120, 4081-4091.
195. Takahashi, R. H., Milner, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, M. F., Xu, H., Greengard, P., and Gouras, G.K. (2002) Intraneuronal Alzheimer Abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 161, 1869-1879.
196. Gúenette, S. Y. (2003) Mechanisms of Abeta clearance and catabolism. Neuromolecular Med. 4, 147-160.
197. Eckman, E. A., and Eckman, C. B. (2005) Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem. Soc. Trans. 33, 1101-1105.
198. Mueller-Steiner, S., Zhou, Y., Arai, H., Roberson, E. D., Sun, B., Chen, J., Wang, X., Yu, G., Esposito, L., Mucke, L., and Gan, L. (2006) Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 51, 703-714.
199. Butler, D., Hwang, J., Estick, C., Nishiyama, A., Kumar, S. S., Baveghems, C., Young-Oxendine, H. B., Wisniewski, M. L., Charalambides, A., and Bahr, B. A. (2011) Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models. PLoS One 6, e20501.
200. Le Blanc, A. C., and Goodyer, C. G. (1999) Role of endoplasmic reticulum, endosomal-lysosomal compartments, and microtubules in amyloid precursor protein metabolism of human neurons. J. Neurochem. 72, 1832-1842.
201. Tian, Y., Bustos, V., Flajolet, M., and Greengard, P. (2011) A smallmolecule enhancer of autophagy decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway. FASEB J. 25, 1934-1942.
202. Yang, D. S., Stavrides, P., Mohan, P. S., Kaushik, S., Kumar, A., Ohno, M., Schmidt, S. D., Wesson, D. W., Bandyopadhyay, U., Jiang, Y., Pawlik, M., Peterhoff, C. M., Yang, A. J., Wilson, D. A., George-Hyslop, P., Westaway, D., Mathews, P. M., Levy, E., Cuervo, A. M., and Nixon, R. A. (2011) Therapeutic effects of remediating autophagy failure in a mouse model of Alzheimerdisease by enhancing lysosomal proteolysis. Autophagy 7, 788-789.
203. Sun, B., Zhou, Y., Halabisky, B., Lo, I., Cho, S. H., Mueller-Steiner, S., Devidze, N., Wang, X., Grubb, A., and Gan, L. (2008) Cystatin Ccathepsin Baxis regulates amyloid beta levels and associated neuronal deficits in ananimalmodel ofAlzheimer'sdisease. Neuron 60, 247-257.
204. Napolitano, G., and Ballabio, A. (2016) TFEB at a glance. J. Cell Sci. 129, 2475-2481.
205. Martini-Stoica, H., Xu, Y., Ballabio, A., and Zheng, H. (2016) The autophagy-lysosomal pathway in neurodegeneration: A TFEB perspective. Trends Neurosci. 39, 221-234.
206. Fraldi, A., Klein, A. D., Medina, D. L., and Settembre, C. (2016) Brain disorders due to lysosomal dysfunction. Annu. Rev. Neurosci. 39, 277-295.
207. Bellettato, C. M., and Scarpa, M. (2010) Pathophysiology of neuropathic lysosomal storage disorders. J. Inherit. Metab. Dis. 33, 347-362.
208. Cherra, S. J. III, Dagda, R. K., and Chu, C. T. (2010) Review: Autophagy and neurodegeneration: survival at a cost? Neuropathol. Appl. Neurobiol. 36, 125-132.
209. McCray, B. A., and Taylor, J. P. (2008) The role of autophagy in agerelated neurodegeneration. Neurosignals 16, 75-84.
210. Nixon, R. A., Yang, D. S., and Lee, J. H. (2008) Neurodegenerative lysosomal disorders: A continuum from development to late age. Autophagy 4, 590-599.
211. Kroemer, G., and Jäattela, M. (2005) Lysosomes and autophagy in cell death control. Nat. Rev. Cancer 5, 886-897.
212. Syntichaki, P., and Tavernarakis, N. (2003) The biochemistry of neuronal necrosis: Rogue biology? Nat. Rev. Neurosci. 4, 672-684.
213. Mullins, C., and Bonifacino, J. S. (2001) The molecular machinery for lysosome biogenesis. Bio Essays 23, 333-343.
214. Spilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., and Galvan, V. (2010) Inhibition of mTOR by rapamycin abolishes cognitive deficits and reducesamyloid-beta levels in amousemodel of Alzheimer'sdisease. PLos One 5, e9979.
215. Garćia-Arencibia, M., Hochfeld, W. E., Toh, P. P., and Rubinsztein, D. C. (2010) Autophagy, a guardian against neurodegeneration. Semin. Cell Dev. Biol. 21, 691-698.
216. Maloney, J. A., Bainbridge, T., Gustafson, A., Zhang, S., Kyauk, R., Steiner, P., van der Brug, M., Liu, Y., Ernst, J. A., Watts, R. J., and Atwal, J. K. (2014) Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. J. Biol. Chem. 289, 30990-31000.
217. Polito, V. A., Li, H., Martini-Stoica, H., Wang, B., Yang, Li., Swartzlander, D. B., Palmieri, M., Di Ronza, A. V. M.-Y., Sardiello, M., Ballabio, A., and Zheng, H. (2014) Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB. Embo. Mol. Med. 6, 1105-1212.